Compare EXTR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXTR | MIRM |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 3.4B |
| IPO Year | 1999 | 2019 |
| Metric | EXTR | MIRM |
|---|---|---|
| Price | $16.91 | $79.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $21.80 | ★ $92.45 |
| AVG Volume (30 Days) | ★ 1.2M | 790.7K |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,181,108,000.00 | $471,794,000.00 |
| Revenue This Year | $12.45 | $53.78 |
| Revenue Next Year | $7.33 | $19.91 |
| P/E Ratio | $282.29 | ★ N/A |
| Revenue Growth | 14.31 | ★ 53.66 |
| 52 Week Low | $10.10 | $36.88 |
| 52 Week High | $22.89 | $79.95 |
| Indicator | EXTR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 69.86 |
| Support Level | $16.57 | $63.23 |
| Resistance Level | $17.29 | $66.77 |
| Average True Range (ATR) | 0.46 | 3.33 |
| MACD | -0.01 | 0.90 |
| Stochastic Oscillator | 18.94 | 98.15 |
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.